You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華仁藥業(300110.SZ):安徽恆星製藥布美他尼原料藥獲得上市申請批準通知書

格隆匯7月2日丨華仁藥業(300110.SZ)公佈,近日,華仁藥業股份有限公司全資子公司安徽恆星製藥有限公司(簡稱“安徽恆星製藥”)收到國家藥品監督管理局覈準簽發的“布美他尼”《化學原料藥上市申請批準通知書》(通知書編號:2025YS00519)。

布美他尼適用於成人嚴重心力衰竭,包括急性肺水腫;成人高血壓,在短期內伴有危及生命的內臟疾病(高血壓急症),尤其是在以下情況下:高血壓腦病,左心室失代償伴肺水腫;成人心臟、腎臟、肝硬化引起的嚴重鈉瀦留。布美他尼是治療急症中應用最多的一類利尿藥,與同類的呋塞米、託拉塞米相比,其利尿作用是呋塞米的20-40倍,對腎功能影響較小,在腎功能衰竭時仍能保持一定的利尿作用,其排鉀作用輕於呋塞米,強於託拉塞米。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account